Clinical trials: Plasma Cell Dyscrasia
Leukemia, Lymphoma
Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00002989
- Testing
- busulfan, cyclophosphamide, idarubicin
- Where
- 9 sites in Belgium, France and 3 more
- Volunteers
- 207 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Multiple Myeloma
Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma
To evaluate the safety and efficacy of Human BCMA Targeted T Cells Injection for the treatment of BCMA-positive relapsed/refractory multiple myeloma.
- Trial name
- NCT04003168
- Testing
- Human BCMA targeted T Cells Injection
- Where
- 3 sites in China
- Volunteers
- 18 people
- Sponsor
- Hrain Biotechnology Co., Ltd.
Multiple Myeloma
BCMA Polymorphisms in Patients With Multiple Myeloma
The aim of this study is to investigate the effect of B cell maturation antigen (BCMA, TNFRSF17) gene polymorphisms on treatment response and survival in patients with multiple myeloma.
- Trial name
- BCMA in MM (NCT07906418)
- Testing
- BCMA polymorphism analysis
- Where
- Turkey (Türkiye)
- Volunteers
- 420 people, healthy volunteers welcome
- Sponsor
- Başakşehir Çam & Sakura City Hospital
Multiple Myeloma
COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
Similar to the paradigm established in other hematologic malignancies that are considered curable, the achievement of MRD(-) status is necessary for long term disease control in MM.
- Trial name
- COMMANDER (NCT05434689)
- Testing
- Iberdomide, Daratumumab, Dexamethasone
- Where
- 4 sites in United States
- Volunteers
- 80 people
- Sponsor
- University of Alabama at Birmingham
Multiple Myeloma and Plasma Cell Neoplasm
Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
RATIONALE: Lenalidomide and dexamethasone may stop the growth of multiple myeloma by blocking blood flow to the tumor. PURPOSE: This phase II trial is studying how well lenalidomide works with or without dexamethasone in treating…
- Trial name
- NCT00772915
- Testing
- dexamethasone, lenalidomide
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- Mayo Clinic
Multiple Myeloma
A Study of VLX1570 and Dexamethasone in Myeloma Patients
This is a phase 1/2 single arm study to determine the safety and efficacy of VLX1570 IV infusion administered with low dose dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma.
- Trial name
- NCT02372240
- Testing
- VLX1570 and dexamethasone
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Vivolux AB
Drug Safety
Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple Myeloma
Primary To evaluate the safety and tolerability of escalating doses of an intravenous (i.v.) infusion of PAT-SM6 in subjects with relapsed or refractory multiple myeloma.
- Trial name
- NCT01727778
- Testing
- Anti-GRP78 monoclonal IgM antibody PAT-SM6
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Patrys Ltd.
Multiple Myeloma, Auto Stem Cell Transplant
Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma
High dose chemotherapy with stem cell transplantation is commonplace in the treatment of multiple myeloma. This treatment uses a chemotherapy drug called Melphalan that has been used in several thousand bone marrow transplant…
- Trial name
- (Mel/MelVel) (NCT01241708)
- Testing
- Bortezomib
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- Hackensack Meridian Health
Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance
The China M-protein Screening Project in First-degree Relatives of Myeloma Patient - The CHAPERONE Study
The goal of the China Monoclonal Gammopathy Screening Project in First-degree Relatives of Patients With Multiple Myeloma (CHAPERONE) study is to assess the clinical significance of screening for monoclonal gammopathy (M-protein)…
- Trial name
- CHAPERONE (NCT05965115)
- Testing
- Sample of Blood
- Where
- China
- Volunteers
- 10,000 people
- Sponsor
- Shanghai Zhongshan Hospital
Multiple Myeloma, Renal Failure
High Dose Therapy Followed by Autologous Transplantation for Myeloma Patients With Severe Renal Impairment
Multiple myeloma (MM) is a malignant plasma cell disorder, characterized by the presence of more than 10 % of clonal plasma cells in the bone marrow.
- Trial name
- IRMYG (NCT03234335)
- Testing
- Data collection
- Where
- 33 sites in Algeria, Belgium and 2 more
- Volunteers
- 50 people
- Sponsor
- Centre Hospitalier Universitaire de Saint Etienne
Multiple Myeloma
Study of Tecemotide (L-BLP25) in Subjects With Slowly Progressive Multiple Myeloma With no Symptoms and Who Have Had no Chemotherapy
Tecemotide (L-BLP25) is believed to induce a Mucinous glycoprotein 1 (MUC1)-specific T-cell response after vaccination. The primary purpose of this study is to ascertain whether vaccination with tecemotide (L-BLP25) induces a…
- Trial name
- NCT01094548
- Testing
- Tecemotide (L-BLP25), Single low dose cyclophosphamide, Multiple low dose cyclophosphamide
- Where
- Germany
- Volunteers
- 34 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Relapsed or Refractory Multiple Myeloma (RRMM)
Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
This is a multicenter, open-label, non-randomized, single-arm clinical trial. Patients with relapsed/refractory multiple myeloma accompanied by extramedullary infiltration will receive BCMA - CD19 CAR-T cell therapy.
- Trial name
- NCT07003555
- Testing
- Dual-targeting BCMA-CD19 CAR-T cell infusion
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Beijing GoBroad Hospital
Multiple Myeloma
ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma
This is a Phase Ib/II safety and efficacy trial of single agent ABC294640, an inhibitor of sphingosine kinase 2 and dihydroceramide desaturase, in refractory or relapsed multiple myeloma (MM).
- Trial name
- ABC-103 (NCT02757326)
- Testing
- Opaganib
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- RedHill Biopharma Limited
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
This phase I trial studies the best dose of CB-839 HCl when given together with carfilzomib and dexamethasone in treating patients with multiple myeloma that has come back or does not respond to previous treatment.
- Trial name
- NCT03798678
- Testing
- Carfilzomib, Dexamethasone, Telaglenastat Hydrochloride
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma and Plasma Cell Neoplasm
Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by…
- Trial name
- NCT00014508
- Testing
- sargramostim, cyclophosphamide, cyclosporine
- Where
- 12 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Multiple Myeloma
Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
The purpose of this phase 1/2, open-label study was to evaluate the effect of oral formulation of Ixazomib when added to standard melphalan and prednisone (MP) treatment.
- Trial name
- NCT01335685
- Testing
- Ixazomib, Melphalan, Prednisone
- Where
- 20 sites in United States, Canada and 3 more
- Volunteers
- 61 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
AL Amyloidosis, POEMS Syndrome
One Gene, Two Diseases: the Pathologic Role of IGLV1-44 in AL Amyloidosis and POEMS
By detailed sequence analysis and subsequent biophysical characterization of prototypic light chains, this project aims to identify sequence fingerprints in IGLV1-44 light chains leading to AL amyloidosis and POEMS syndrome.
- Conditions
- AL Amyloidosis, POEMS Syndrome, Multiple Myeloma
- Trial name
- ALPS (NCT07448935)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Multiple Myeloma
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
The main purpose of this study is to see how well a new treatment ramantamig-D works compared to standard treatments that is either DVRd or DRd on progression-free survival (PFS; time until a participant's disease worsens) and…
- Trial name
- TRIlogy-7 (NCT07665450)
- Testing
- Ramantamig, Daratumumab, Lenalidomide
- Where
- 103 sites in Australia, Czechia and 12 more
- Volunteers
- 1,000 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma
Study of Combination PS-341 and Thalidomide in Multiple Myeloma
The purpose of this study is to assess the toxicity of PS-341 combined with one of four doses of thalidomide in patients with refractory multiple myeloma, and to find the most appropriate doses of PS-341 and thalidomide in the…
- Trial name
- NCT00083460
- Testing
- PS-341, Thalidomide, Dexamethasone
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- University of Arkansas
Relapsed or Refractory Multiple Myeloma
A Study of JNJ-87562761 in Participants With Relapsed or Refractory Multiple Myeloma
The purpose of this study is to determine the recommended phase 2 dose(s) (RP2D[s]) of JNJ-87562761 in Part 1 (dose escalation), and to determine the safety and tolerability at RP2D in Part 2 (dose expansion) in participants with…
- Trial name
- NCT06604715
- Testing
- JNJ-87562761
- Where
- 15 sites in Canada, South Korea and 2 more
- Volunteers
- 17 people
- Sponsor
- Janssen Research & Development, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.